RxDoctor Payments Data

Christian Cabrera Kang, MD

Neurology · Atlanta, GANPI 1134419088

Payments from drug & device makers

$13,082in general payments, 2019–2025

Across 653 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Acadia Pharmaceuticals Inc$784
  • UCB, Inc.$725
  • MDD US Operations, LLC$719
  • Pfizer$624
  • Amgen$536
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$13,074100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)150$2,493
Acadia Pharmaceuticals Inc33$784
UCB, Inc.34$725
MDD US Operations, LLC12$719
Pfizer39$624
Amgen(2 entities)28$536
Biogen26$498
Teva Pharmaceuticals USA, Inc.27$476
Novartis25$468
Lilly USA, LLC24$382
Argenx US, Inc.13$347
Lundbeck LLC13$296
Bristol Myers Squibb12$296
Eisai Inc.10$273
Genentech USA, Inc.12$232
Otsuka America Pharmaceutical, Inc.9$225
Supernus Pharmaceuticals, Inc.10$211
Sanofi11$198
TG Therapeutics, Inc.6$174
Neurocrine Biosciences, Inc.7$173
Grifols USA, LLC8$165
Biohaven Pharmaceutical Holding Company Ltd.10$162
AstraZeneca(2 entities)9$157
Johnson & Johnson(2 entities)9$153
Kyowa Kirin, Inc.8$135
Biohaven Pharmaceuticals, Inc.7$132
SK Life Science, Inc.4$123
EMD Serono, Inc.7$116
Novo Nordisk6$101
Neurelis, Inc.4$98
CSL Behring3$82
Harmony Biosciences LLC4$79
Boehringer Ingelheim4$77
Avanir Pharmaceuticals, Inc.4$75
Amneal Pharmaceuticals LLC4$68
Adamas Pharmaceuticals, Inc.4$64
Axsome Therapeutics, Inc.2$64
Sunovion Pharmaceuticals Inc.4$62
Avion Pharmaceuticals4$61
Alnylam Pharmaceuticals Inc.2$59
Acorda Therapeutics, Inc3$55
Upsher-smith Laboratories LLC3$52
Genentech, Inc.1$50
Sumitomo Pharma America, Inc.2$48
Merz Pharmaceuticals, LLC2$47
Merck3$41
Jazz Pharmaceuticals Inc.2$40
GE HealthCare2$37
Takeda Pharmaceuticals U.S.A., Inc.1$35
Arbor Pharmaceuticals, Inc.2$32
Impel Pharmaceuticals Inc.1$31
Springworks Therapeutics, Inc.1$31
Azurity Pharmaceuticals, Inc.2$29
Catalyst Pharmaceuticals, Inc.1$27
Dynavax Technologies Corporation1$26
Inspire Medical Systems, Inc.1$26
Medtronic1$24
Bayer1$24
Smith+Nephew1$23
Bausch Health US, LLC1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,082 in reported general payments places this provider in the 75th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$198,100
Medicare patients
491
Services billed
8,837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UltomirisRavulizumab-Cwvz13$415,927
Gamunex-CImmune Globul G/Gly/Iga Avg 4645$361,155
AustedoDeutetrabenazine12$176,588
FycompaPerampanel29$44,984
BriviactBrivaracetam13$20,504
EliquisApixaban13$17,561
RytaryCarbidopa/Levodopa15$17,114
Rivastigmine81$14,790
Memantine Hcl286$11,036
Rasagiline Mesylate21$8,094
Carbidopa-LevodopaCarbidopa/Levodopa186$8,019
RivastigmineRivastigmine Tartrate83$5,903
Gabapentin250$5,817
Lamotrigine ErLamotrigine20$5,399
Duloxetine Hcl220$4,832

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaUltomiris$157$415,92713 claims
Grifols USA, LLCGamunex-C$165$361,15545 claims
Teva Pharmaceuticals USA, Inc.Austedo$476$176,58812 claims
Eisai Inc.Fycompa$273$44,98429 claims
UCB, Inc.Briviact$725$20,50413 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$68$19,45426 claims
PfizerEliquis$624$17,56113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 506 neurology providers in Georgia.

Other neurology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →